As Q1 wraps up, we’re seeing a market that’s growing increasingly cautious. The year kicked off with a sense of optimism—public markets surged in late 2024, investors were pricing in aggressive Fed rate cuts, and policy signals from the new administration suggested a more business-friendly, pro-growth stance.
Those sentiments have subsided. Both the S&P 500 and Nasdaq just posted their worst quarters since 2022, falling 4.6% and 10% respectively, given Trump’s tariff whiplash, recession fears, and faltering confidence in the U.S. AI trade. This turn in sentiment is also reflected in the private markets.
According to an HSBC survey, which captures the views of 184 global investors representing $1.87 trillion in AUM between Feb 24 and Mar 17, only 47% of private market investors now expect activity to increase in the next quarter, down from 53% just a few months ago. Meanwhile, 65% of investors plan to exit a portfolio company in the next 12 months—down from 77%—suggesting a more selective approach to liquidity. With U.S. PE dry powder exceeding $1 trillion, deployment appetite appears strong, but with greater scrutiny on valuation, structure, and macro headwinds.
Here are some of the highlights from the quarter.
Deal and Exit Activity Rose in Q1 2025
In Q1 2025, U.S. private equity deal activity rose to 1,225 transactions, up from 1,116 in Q1 2024. Exit activity also improved to 193 deals, compared to 161 a year prior.
The uptick is likely driven in part by more favorable pricing conditions as sellers—pressured by extended hold periods and rising debt costs—become more flexible on valuations. With over 3,800 PE-backed companies held beyond five years and delinquency rates climbing, capital-constrained owners are increasingly motivated to transact.
This shift is opening the door for buyers to act on high-conviction opportunities. A prime example: Sycamore Partners’ $23.7 billion take-private of Walgreens Boots Alliance, the largest healthcare buyout since the financial crisis.
Macro Pressures Remain a Headwind
Despite improved pricing, credit conditions remain challenging. Consumer loan delinquencies reached 2.75% by the end of 2024—the highest in a decade. Business loan delinquencies rose to 1.28%, pointing to tightening credit and heightened refinancing risk for leveraged companies.
Federal interest outlays have also climbed to 3.1% of GDP, surpassing national defense spending. With elevated rates expected to persist, debt service costs are becoming a drag on both portfolio company performance and deal structuring.
VC-Backed Companies are Driving M&A
In 2024, there were 956 acquisitions of VC-backed companies, and notably, 33.7% of those deals were led by other VC-backed firms—a historic high. This marks a shift in market structure: with Big Tech making just 17 acquisitions, the lowest total in over a decade, mature private companies are now filling the strategic buyer gap.
These buyers—like Databricks, Stripe, and Automattic—have raised substantial capital and are deploying it to consolidate markets, expand product offerings, and accelerate growth.
IPO Market Still Quite, But Optimism Building
Despite weak overall liquidity, 58% of VC/PE investors expect IPO activity to rise in 2025, particularly in AI, cybersecurity, and fintech. A narrowing bid-ask spread and improved governance among later-stage companies are creating conditions for select IPOs to proceed.
That said, capital remains cautious. Flat rounds are increasingly common, and most sectors outside healthcare are relying on previously raised funds. Still, 38% of VC investors report higher dry powder levels—a signal that capital is ready, but waiting for the right conditions.
Tech Appetite Cools, Healthcare Booms
Investor sentiment toward technology has cooled. Bullishness among private market investors dropped to 54%, down from 65% in late 2024. Concerns around valuations, regulatory scrutiny, and geopolitical risk—particularly with tariffs expected on semiconductors and AI hardware—are dampening near-term enthusiasm.
In contrast, healthcare is emerging as a relative bright spot. 85% of public market investors are bullish on healthcare equities, and while private investors remain cautious due to slow deal flow, the sector continues to be the most overweight in PE/VC portfolios—driven by lower valuations and innovation in therapeutics and diagnostics.
What This Means
After years of inflated valuation expectations and wide bid-ask spreads that stalled deal flow, sellers are increasingly meeting the market—pressured by rising capital costs, maturing fund timelines, and tighter credit conditions. Recent reports confirm that valuation gaps, which widened significantly in 2022 and 2023, are now beginning to narrow, creating a more functional environment for both buyouts and strategic exits.
Early 2025 deal activity reflects this shift, aided in part by improved pricing dynamics, easing regulatory conditions, and a policy backdrop seen as more business-friendly under the returning Trump administration. Yet caution prevails, and GPs are reserving their dry powder for high-conviction situations where value creation is clear.
In venture, the shift toward VC-backed acquirers is becoming structural, as scaled startups consolidate markets in the absence of Big Tech buyers. Across both asset classes, the path forward will likely be shaped by underwriting discipline, timing precision, and a renewed focus on fundamentals.
Sources:
– PitchBook. US PE Pulse: Q1 2025 Analyst Note. March 2025.
– PitchBook. VC-Backed Companies Taking Advantage of Slow M&A Market: Q1 2025 Analyst Note. March 2025.
– HSBC Global Research. Funding the Future: What investors are saying about capital markets in 2025. March 2025.
– Financial Times. Private equity faces third year of payout shortfalls as higher rates hit deals. March 11, 2025
– Commonfund. Private Equity 2024 Year in Review and Looking Forward. January 2025
– Moonfare. Private Equity Outlook 2025: What to Expect in the Year Ahead. February 2025.
